Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients by Gradman Alan H, Schmieder Roland E, Lins Robert L, Nussberger Juerg, Chiang Yanntong, Bedigian Martin P in Circulation (2005).

[PMID: 15723979] PubMed


Stopping the detrimental effects of the renin-angiotensin system at the most upstream point of the cascade offers theoretical advantages for cardiovascular protection. This study compares the antihypertensive efficacy and safety of the novel oral renin inhibitor aliskiren with placebo and an active comparator.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.